Valuation: Cytokinetics, Incorporated

Market Cap 8.76B 7.84B 7.21B 6.54B 12.22B 831B 12.45B 86.03B 34.54B 437B 32.86B 32.17B 1,379B P/E 2026 *
-10.3x
P/E 2027 * -13.7x
Enterprise Value 7.6B 6.8B 6.26B 5.67B 10.6B 721B 10.8B 74.61B 29.95B 379B 28.5B 27.9B 1,196B EV / Sales 2026 *
48.6x
EV / Sales 2027 * 18x
Free-Float
98.21%
Yield 2026 *
-
Yield 2027 * -
1 day-0.51%
1 week+2.87%
1 month-4.43%
3 months-18.33%
6 months-1.53%
Current year-0.87%
1 week 60.14
Extreme 60.145
64.5
1 month 59.78
Extreme 59.785
66.91
Current year 58.43
Extreme 58.43
88.31
1 year 58.05
Extreme 58.05
88.31
3 years 29.31
Extreme 29.31
110.25
5 years 25.98
Extreme 25.98
110.25
10 years 5.75
Extreme 5.75
110.25
Manager TitleAgeSince
Chief Executive Officer 62 2006-12-31
Director of Finance/CFO 55 2024-05-07
Chief Operating Officer - 2018-02-28
Director TitleAgeSince
Director/Board Member 62 2006-12-31
Chairman 81 2022-04-07
Director/Board Member 78 2011-02-08
Date Insider Type Main position Quantity % Market Cap. Importance
10/12/26 Exercice

Chief Executive Officer

22,500 0.0162%
10/6/26 Exercice

Chief Technology Officer

10,500 0.0076%
9/28/26 Exercice

Chief Executive Officer

22,500 0.0162%
Change 5-day change 1-year change 3-year change Capi.($)
-0.51%+2.87%-0.94%+80.69% 8.76B
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average +0.25%+7.07%+42.73%+183.56% 40.31B
Weighted average by Cap. +0.16%+5.39%+46.93%+174.58%

Financials

2026 *2027 *
Net sales 156M 140M 129M 117M 218M 14.84B 222M 1.54B 617M 7.81B 587M 574M 24.63B 429M 384M 353M 320M 598M 40.7B 609M 4.21B 1.69B 21.41B 1.61B 1.57B 67.51B
Net income -805M -721M -663M -601M -1.12B -76.39B -1.14B -7.9B -3.17B -40.18B -3.02B -2.96B -127B -652M -584M -537M -486M -909M -61.88B -926M -6.4B -2.57B -32.55B -2.45B -2.39B -103B
Net Debt -1.16B -1.04B -957M -867M -1.62B -110B -1.65B -11.42B -4.58B -58.04B -4.36B -4.27B -183B -1.06B -953M -876M -794M -1.48B -101B -1.51B -10.45B -4.19B -53.12B -3.99B -3.91B -168B
Projected Income Statement - Annual - Cytokinetics, Incorporated
Logo Cytokinetics, Incorporated
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
Employees
673
Date Price Change Volume
26-10-30 US$62.99 -0.51% 1,257,213
26-10-29 US$63.31 +3.31% 1,425,390
26-10-28 US$61.28 -0.39% 1,274,169
26-10-27 US$61.52 +1.30% 1,148,268
26-10-26 US$60.73 -0.82% 783,238
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - Cytokinetics, Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
62.99USD
Average target price
107.39USD
Spread / Average Target
+70.49%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cytokinetics, Incorporated
  1. Stock Market
  2. Stocks
  3. CYTK Stock